LIXT: Lixte Biotechnology Holdings Inc. Short-Term Debt to Equity

Lixte Biotechnology - graphic logo of issuer LIXT

This Lixte Biotechnology (LIXT) price chart on the GURU.Markets platform reflects the asset's dynamics, with a current valuation of 0.07. The business relies on the development of protein phosphatase inhibitors, creating a critical dependency on the success of a single drug. Lixte Biotechnology develops anti-tumor agents in US centers utilizing enzyme blocking. However, a narrow development pipeline and high capital requirements increase the probability of delisting.

LIXT (Lixte Biotechnology Holdings) Current Liabilities to Capital history from 07/04/2022 to 07/06/2026

Analytical breakdowns for lixte.com (LIXT)

- price and consensus price forecast:
Stock Price Lixte Biotechnology Holdings|LIXT - Average Forecast Price
- market capitalization data:
Market Value Lixte Biotechnology Holdings Inc.|LIXT - Business Value
- book capitalization data:
Book Value per Share Lixte Biotechnology|LIXT - Total Stockholders' Equity|Market Value to Book Value Ratio lixte.com|LIXT - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Lixte Biotechnology|LIXT - Long-Term Debt to Capital|Short-Term Debt to Equity Lixte Biotechnology Holdings, Inc.|LIXT - Company Debts|Debt to Book Value Lixte Biotechnology Holdings Inc.|LIXT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Lixte Biotechnology
Fundamental company analysis:Lixte Biotechnology
Brand item of Lixte Biotechnology Holdings, Inc.

By outsourcing drug synthesis to external CDMO partners, Lixte Biotechnology (LIXT) minimizes capital expenditures on production. By analyzing the ratio of short-term loans to equity on GURU.Markets, an investor assesses the company's reliance on short-term liabilities relative to its capital, which helps identify the risk of cash flow gaps and confirm the asset's financial stability during clinical trial periods.

Competing companies

Incyte Corp. - Short-Term Debt to Capital|Current Liabilities to Capital HCM (HUTCHMED Corp)|NUVB - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio dayonebio.com DAWN|MNPR (Monopar Therapeutics Inc.) - Short-Term Debt to Capital|INBX: Current Liabilities to Capital|Short-Term Debt to Equity i-mabbiopharma.com IMAB|Fennec (FENC) - Ratio of Short-Term Indebtedness to Capital|HRTX (Heron) - Short-Term Debt to Capital|Short-Term Debt to Capital NVCT|Short-Term Debt to Equity Coherus BioSciences, Inc (CHRS)|Short-Term Debt to Equity Corbus Pharmaceuticals Holdings, Inc. CRBP|Short-Term Debt to Equity Ratio Cardiff Oncology|BeyondSpring Inc - Ratio of Short-Term Indebtedness to Capital|BCAB (BioAtla Corp) - Short-Term Debt to Equity|CTXR: Current Liabilities to Capital|Short-Term Debt to Equity Cellectar Biosciences, Inc.|BioLineRx Ltd (BLRX) - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CANF|Short-Term Debt to Equity Ratio APRE|Kazia Therapeutics - Short-Term Debt to Equity|Current Liabilities to Capital SLXN (silexion.com)|Short-Term Debt to Equity NuCana NCNA|Chimerix Inc. - Short-Term Debt to Equity|CYCC (Cyclacel Pharmaceuticals Inc.) - Short-Term Debt to Equity|GTHX - Current Liabilities to Capital|Short-Term Debt to Capital KRON (Kronos Bio, Inc.)|Short-Term Indebtedness to Equity kintara.com|Short-Term Debt to Equity Ratio ONCT (Oncternal Therapeutics, Inc.)|Current Liabilities to Capital Portage Biotech Inc (PRTG)